Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Patients with newly diagnosed B-cell acute lymphoblastic leukemia received up to four cycles of hyper-CVAD followed by four cycles of blinatumomab. Inotuzumab ozogamicin 0.3 mg/m2 was added on days one and eight to two cycles of high-dose methotrexate and cytarabine, and two cycles of blinatumomab.